Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Newegg Commerce Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Newegg Commerce Inc trades at $14.15 (market cap $300.34M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 132.8× Newegg Commerce Inc's market cap, and Alnylam Pharmaceuticals, Inc. is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| ALNY | NEGG | |
|---|---|---|
Market Cap | $39.89B | $300.34M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $128.09 |
52-Week Low | $278.09 | $14.15 |
Enterprise Value | $38.15B | $299.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NEGG trades at $14.15, down 4.2% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $4.88M in 2025, though revenue was $1.44B and the net margin improved to -0.34%. Recent news highlights AI shopping features and sales events, while cash flow trends show operational challenges but financing support.
The outlook remains cautious; while valuation ratios like P/S of 0.21 appear low, profitability is weak and cash burn persists. Risks include competitive pressures and execution hurdles, but a sole analyst rates it Buy. Investors should weigh cost controls against sustained losses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
